Global Neuropathic Pain Market: Industry Analysis and Forecast (2019-2026) – By Type, Indication, Diagnosis, Treatment, Distribution Channel, End-User and Region

Global Neuropathic Pain Market was valued US$ XX Bn in 2019 and is expected to reach US$ Bn 9.20 by 2026, at a CAGR of around XX % during a forecast period. Neuropathic pain caused by damage or disease affecting the somatosensory nervous structure. The neuropathic pain may be associated with abnormal sensations known as dysesthesia pain. Neuropathic pain can be contrasted to nociceptive pain, which occurs when someone experiences an acute injury, such as smashing a finger with a hammer or knocking a toe when walking barefoot. This type of pain is typically short-lived and generally quite responsive to common pain medications indifference to neuropathic pain. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region The increasing geriatric population across the globe is anticipated to drive the demand for the prevalence of painful diabetic neuropathy which is in the global elderly peoples suffering from diabetes. Rising prevalence of diabetes and cancer, approval of different treatment opportunities for neuropathic pain, rise in the number of pain management centers are the major factors expected to drive the growth of the global neuropathic pain organization market. However, the neuropathic pain market restraints are the high cost of neuropathy pain treatment and lack of health infrastructure. The report covers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a significant role in the enlargement of the market from 2019 to 2026. Peripheral Neuropathy segment is expected as the leading segment in the neuropathic pain market during the forecast period. Peripheral neuropathy mainly causes due to damage that occurred to peripheral nerves subsequent in weakness, numbness, and usually in hands and feet. Peripheral neuropathy is caused because of traumatic injuries, infections, metabolic problems, inherited causes and exposure to toxins, and most commonly by diabetes mellitus. Thus, the rising prevalence of diabetes mellitus is expected to increase the population of patients suffering from peripheral neuropathy. By Indication, the diabetic neuropathy segment is held to dominate the xx% market share during the forecast period. Diabetic neuropathy furthermost often damages nerves in your legs and feet. Depending on the affected nerves, indications of diabetic neuropathy can variety from pain and shocks in your legs, blood vessels and heart. Diabetic neuropathy is a common complication of diabetes. But you can frequently check diabetic neuropathy or slow its progress with constricted blood sugar control. North America region is expected to hold a dominant position in the Global Data Integration Market. The data integration market in North America region is highly competitive the developed countries like the US and Canada have invested significantly in research and development (R&D) activities, which are expected to share significant growth in the regional market. These countries are initial adopters of knowledge in various verticals. The US and Canada are also the top countries in hospitals, clinics, research organizations, and other productions. The objective of the report is to present a complete calculation of the Global Neuropathic Pain Market and contains thoughtful insights, historical data, facts, industry-validated market data and plans with a suitable set of assumptions and methodology. The report also helps in the Global Neuropathic Pain Market is a dynamic structure by identifying and analyzing the market segments and project the global market size. The additional, report also focuses on the competitive analysis of key player’s by-product, financial position, price, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Global Neuropathic Pain Market.

Scope of the Global Neuropathic Pain Market

Global Neuropathic Pain Market, By Type

• Peripheral Neuropathy • Entrapment Neuropathy • Phantom Limb Pain • Trigeminal Neuralgia • Post Herpetic Neuralgia • Post Traumatic Neuropathy

Global Neuropathic Pain Market, By Indication

• Diabetic Neuropathy • Chemotherapy-Induced Peripheral Neuropathy • Spinal Stenosis

Global Neuropathic Pain Market, By Diagnosis

• Imaging • Physical Examination • Blood Tests

Global Neuropathic Pain Market, By Treatment

• Medication • Multimodal Therapy

Global Neuropathic Pain Market, By Distribution Channel

• Online Pharmacies • Retail Pharmacies • Drug Stores • Others

Global Neuropathic Pain Market, By End-User

• Hospitals • Clinics • Research Organizations • Others

Global Neuropathic Pain Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in the Global Neuropathic Pain Market

• Pfizer Inc. • Johnson and Johnson Services Inc. • Eli Lily and Company • GlaxoSmithKline PLC • Bristol-Myers Squibb • Sanofi SA • Baxter Healthcare Corporation • Biogen Idec Inc. • Astellas Pharma Inc. • AstraZeneca • Abbott Laboratories • Teva Pharmaceutical Industries Ltd • Depomed Inc. • Neuroheal Biomedicals, S.L., • Mylan N.V. • ZydusCadila • Amneal Pharmaceuticals LLC • Mayne Pharma Group Limited • Aurobindo Pharma • aurolife, • Mallinckrodt plc • Hikma Pharmaceuticals PLC • ANI Pharmaceuticals, Inc Key Developments:
Global Neuropathic Pain Market Table of Content 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Neuropathic Pain Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Neuropathic Pain Market Analysis and Forecast 6.1. Global Neuropathic Pain Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Neuropathic Pain Market Analysis and Forecast, by Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Neuropathic Pain Market Value Share Analysis, by Type 7.4. Global Neuropathic Pain Market Size (US$ Bn) Forecast, by Type 7.5. Global Neuropathic Pain Market Analysis, by Type 7.6. Global Neuropathic Pain Market Attractiveness Analysis, by Type 8. Global Neuropathic Pain Market Analysis and Forecast, by Indication 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Neuropathic Pain Market Value Share Analysis, by Indication 8.4. Global Neuropathic Pain Market Size (US$ Bn) Forecast, by Indication 8.5. Global Neuropathic Pain Market Analysis, by Indication 8.6. Global Neuropathic Pain Market Attractiveness Analysis, by Indication 9. Global Neuropathic Pain Market Analysis and Forecast, by Diagnosis 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Neuropathic Pain Market Value Share Analysis, by Diagnosis 9.4. Global Neuropathic Pain Market Size (US$ Bn) Forecast, by Diagnosis 9.5. Global Neuropathic Pain Market Analysis, by Diagnosis 9.6. Global Neuropathic Pain Market Attractiveness Analysis, by Diagnosis 10. Global Neuropathic Pain Market Analysis and Forecast, by Treatment 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Neuropathic Pain Market Value Share Analysis, by Treatment 10.4. Global Neuropathic Pain Market Size (US$ Bn) Forecast, by Treatment 10.5. Global Neuropathic Pain Market Analysis, by Treatment 10.6. Global Neuropathic Pain Market Attractiveness Analysis, by Treatment 11. Global Neuropathic Pain Market Analysis and Forecast, By Distribution Channel 11.1. Introduction and Definition 11.2. Key Findings 11.3. Global Neuropathic Pain Market Value Share Analysis, By Distribution Channel 11.4. Global Neuropathic Pain Market Size (US$ Bn) Forecast, By Distribution Channel 11.5. Global Neuropathic Pain Market Analysis, By Distribution Channel 11.6. Global Neuropathic Pain Market Attractiveness Analysis, By Distribution Channel 12. Global Neuropathic Pain Market Analysis and Forecast, by End-User 12.1. Introduction and Definition 12.2. Key Findings 12.3. Global Neuropathic Pain Market Value Share Analysis, by End-User 12.4. Global Neuropathic Pain Market Size (US$ Bn) Forecast, by End-User 12.5. Global Neuropathic Pain Market Analysis, by End-User 12.6. Global Neuropathic Pain Market Attractiveness Analysis, by End-User 13. Global Neuropathic Pain Market Analysis, by Region 13.1. Global Neuropathic Pain Market Value Share Analysis, by Region 13.2. Global Neuropathic Pain Market Size (US$ Bn) Forecast, by Region 13.3. Global Neuropathic Pain Market Attractiveness Analysis, by Region 14. North America Neuropathic Pain Market Analysis 14.1. Key Findings 14.2. North America Neuropathic Pain Market Overview 14.3. North America Neuropathic Pain Market Value Share Analysis, by Type 14.4. North America Neuropathic Pain Market Forecast, by Type 14.4.1. Peripheral Neuropathy 14.4.2. Entrapment Neuropathy 14.4.3. Phantom Limb Pain 14.4.4. Trigeminal Neuralgia 14.4.5. Post Herpetic Neuralgia 14.4.6. Post Traumatic Neuropathy 14.5. North America Neuropathic Pain Market Value Share Analysis, by Indication 14.6. North America Neuropathic Pain Market Forecast, by Indication 14.6.1. Diabetic Neuropathy 14.6.2. Chemotherapy-Induced Peripheral Neuropathy 14.6.3. Spinal Stenosis 14.7. North America Neuropathic Pain Market Value Share Analysis, by Diagnosis 14.8. North America Neuropathic Pain Market Forecast, by Diagnosis 14.8.1. Imaging 14.8.2. Physical Examination 14.8.3. Blood Tests 14.9. North America Neuropathic Pain Market Value Share Analysis, by Treatment 14.10. North America Neuropathic Pain Market Forecast, by Treatment 14.10.1. Medication 14.10.2. Multimodal Therapy 14.11. North America Neuropathic Pain Market Value Share Analysis, By Distribution Channel 14.12. North America Neuropathic Pain Market Forecast, By Distribution Channel 14.12.1. Online Pharmacies 14.12.2. Retail Pharmacies 14.12.3. Drug Stores 14.12.4. Others 14.13. North America Neuropathic Pain Market Value Share Analysis, by End-User 14.14. North America Neuropathic Pain Market Forecast, by End-User 14.14.1. Hospitals 14.14.2. Clinics 14.14.3. Research Organizations 14.14.4. Others 14.15. North America Neuropathic Pain Market Value Share Analysis, by Country 14.16. North America Neuropathic Pain Market Forecast, by Country 14.16.1. U.S. 14.16.2. Canada 14.17. North America Neuropathic Pain Market Analysis, by Country 14.18. U.S. Neuropathic Pain Market Forecast, by Type 14.18.1. Peripheral Neuropathy 14.18.2. Entrapment Neuropathy 14.18.3. Phantom Limb Pain 14.18.4. Trigeminal Neuralgia 14.18.5. Post Herpetic Neuralgia 14.18.6. Post Traumatic Neuropathy 14.19. U.S. Neuropathic Pain Market Forecast, by Indication 14.19.1. Diabetic Neuropathy 14.19.2. Chemotherapy-Induced Peripheral Neuropathy 14.19.3. Spinal Stenosis 14.20. U.S. Neuropathic Pain Market Forecast, by Diagnosis 14.20.1. Imaging 14.20.2. Physical Examination 14.20.3. Blood Tests 14.21. U.S. Neuropathic Pain Market Forecast, by Treatment 14.21.1. Medication 14.21.2. Multimodal Therapy 14.22. U.S. Neuropathic Pain Market Forecast, By Distribution Channel 14.22.1. Online Pharmacies 14.22.2. Retail Pharmacies 14.22.3. Drug Stores 14.22.4. Others 14.23. U.S. Neuropathic Pain Market Forecast, by End-User 14.23.1. Hospitals 14.23.2. Clinics 14.23.3. Research Organizations 14.23.4. Others 14.24. Canada Neuropathic Pain Market Forecast, by Type 14.24.1. Peripheral Neuropathy 14.24.2. Entrapment Neuropathy 14.24.3. Phantom Limb Pain 14.24.4. Trigeminal Neuralgia 14.24.5. Post Herpetic Neuralgia 14.24.6. Post Traumatic Neuropathy 14.25. Canada Neuropathic Pain Market Forecast, by Indication 14.25.1. Diabetic Neuropathy 14.25.2. Chemotherapy-Induced Peripheral Neuropathy 14.25.3. Spinal Stenosis 14.26. Canada Neuropathic Pain Market Forecast, by Diagnosis 14.26.1. Imaging 14.26.2. Physical Examination 14.26.3. Blood Tests 14.27. Canada Neuropathic Pain Market Forecast, by Treatment 14.27.1. Medication 14.27.2. Multimodal Therapy 14.28. Canada Neuropathic Pain Market Forecast, By Distribution Channel 14.28.1. Online Pharmacies 14.28.2. Retail Pharmacies 14.28.3. Drug Stores 14.28.4. Others 14.29. Canada Neuropathic Pain Market Forecast, by End-User 14.29.1. Hospitals 14.29.2. Clinics 14.29.3. Research Organizations 14.29.4. Others 14.30. North America Neuropathic Pain Market Attractiveness Analysis 14.30.1. By Type 14.30.2. By Indication 14.30.3. By Diagnosis 14.30.4. By Treatment 14.30.5. By Distribution Channel 14.30.6. By End-User 14.31. PEST Analysis 15. Europe Neuropathic Pain Market Analysis 15.1. Key Findings 15.2. Europe Neuropathic Pain Market Overview 15.3. Europe Neuropathic Pain Market Value Share Analysis, by Type 15.4. Europe Neuropathic Pain Market Forecast, by Type 15.4.1. Peripheral Neuropathy 15.4.2. Entrapment Neuropathy 15.4.3. Phantom Limb Pain 15.4.4. Trigeminal Neuralgia 15.4.5. Post Herpetic Neuralgia 15.4.6. Post Traumatic Neuropathy 15.5. Europe Neuropathic Pain Market Value Share Analysis, by Indication 15.6. Europe Neuropathic Pain Market Forecast, by Indication 15.6.1. Diabetic Neuropathy 15.6.2. Chemotherapy-Induced Peripheral Neuropathy 15.6.3. Spinal Stenosis 15.7. Europe Neuropathic Pain Market Value Share Analysis, by Diagnosis 15.8. Europe Neuropathic Pain Market Forecast, by Diagnosis 15.8.1. Imaging 15.8.2. Physical Examination 15.8.3. Blood Tests 15.9. Europe Neuropathic Pain Market Value Share Analysis, by Treatment 15.10. Europe Neuropathic Pain Market Forecast, by Treatment 15.10.1. Medication 15.10.2. Multimodal Therapy 15.11. Europe Neuropathic Pain Market Value Share Analysis, By Distribution Channel 15.12. Europe Neuropathic Pain Market Forecast, By Distribution Channel 15.12.1. Online Pharmacies 15.12.2. Retail Pharmacies 15.12.3. Drug Stores 15.12.4. Others 15.13. Europe Neuropathic Pain Market Value Share Analysis, by End-User 15.14. Europe Neuropathic Pain Market Forecast, by End-User 15.14.1. Hospitals 15.14.2. Clinics 15.14.3. Research Organizations 15.14.4. Others 15.15. Europe Neuropathic Pain Market Value Share Analysis, by Country 15.16. Europe Neuropathic Pain Market Forecast, by Country 15.16.1. Germany 15.16.2. U.K. 15.16.3. France 15.16.4. Italy 15.16.5. Spain 15.16.6. Rest of Europe 15.17. Europe Neuropathic Pain Market Analysis, by Country 15.18. Germany Neuropathic Pain Market Forecast, by Type 15.18.1. Peripheral Neuropathy 15.18.2. Entrapment Neuropathy 15.18.3. Phantom Limb Pain 15.18.4. Trigeminal Neuralgia 15.18.5. Post Herpetic Neuralgia 15.18.6. Post Traumatic Neuropathy 15.19. Germany Neuropathic Pain Market Forecast, by Indication 15.19.1. Diabetic Neuropathy 15.19.2. Chemotherapy-Induced Peripheral Neuropathy 15.19.3. Spinal Stenosis 15.20. Germany Neuropathic Pain Market Forecast, by Diagnosis 15.20.1. Imaging 15.20.2. Physical Examination 15.20.3. Blood Tests 15.21. Germany Neuropathic Pain Market Forecast, by Treatment 15.21.1. Medication 15.21.2. Multimodal Therapy 15.22. Germany Neuropathic Pain Market Forecast, By Distribution Channel 15.22.1. Online Pharmacies 15.22.2. Retail Pharmacies 15.22.3. Drug Stores 15.22.4. Others 15.23. Germany Neuropathic Pain Market Forecast, by End-User 15.23.1. Hospitals 15.23.2. Clinics 15.23.3. Research Organizations 15.23.4. Others 15.24. U.K. Neuropathic Pain Market Forecast, by Type 15.24.1. Peripheral Neuropathy 15.24.2. Entrapment Neuropathy 15.24.3. Phantom Limb Pain 15.24.4. Trigeminal Neuralgia 15.24.5. Post Herpetic Neuralgia 15.24.6. Post Traumatic Neuropathy 15.25. U.K. Neuropathic Pain Market Forecast, by Indication 15.25.1. Diabetic Neuropathy 15.25.2. Chemotherapy-Induced Peripheral Neuropathy 15.25.3. Spinal Stenosis 15.26. U.K. Neuropathic Pain Market Forecast, by Diagnosis 15.26.1. Imaging 15.26.2. Physical Examination 15.26.3. Blood Tests 15.27. U.K. Neuropathic Pain Market Forecast, by Treatment 15.27.1. Medication 15.27.2. Multimodal Therapy 15.28. U.K. Neuropathic Pain Market Forecast, By Distribution Channel 15.28.1. Online Pharmacies 15.28.2. Retail Pharmacies 15.28.3. Drug Stores 15.28.4. Others 15.29. U.K. Neuropathic Pain Market Forecast, by End-User 15.29.1. Hospitals 15.29.2. Clinics 15.29.3. Research Organizations 15.29.4. Others 15.30. France Neuropathic Pain Market Forecast, by Type 15.30.1. Peripheral Neuropathy 15.30.2. Entrapment Neuropathy 15.30.3. Phantom Limb Pain 15.30.4. Trigeminal Neuralgia 15.30.5. Post Herpetic Neuralgia 15.30.6. Post Traumatic Neuropathy 15.31. France Neuropathic Pain Market Forecast, by Indication 15.31.1. Diabetic Neuropathy 15.31.2. Chemotherapy-Induced Peripheral Neuropathy 15.31.3. Spinal Stenosis 15.32. France Neuropathic Pain Market Forecast, by Diagnosis 15.32.1. Imaging 15.32.2. Physical Examination 15.32.3. Blood Tests 15.33. France Neuropathic Pain Market Forecast, by Treatment 15.33.1. Medication 15.33.2. Multimodal Therapy 15.34. France Neuropathic Pain Market Forecast, By Distribution Channel 15.34.1. Online Pharmacies 15.34.2. Retail Pharmacies 15.34.3. Drug Stores 15.34.4. Others 15.35. France Neuropathic Pain Market Forecast, by End-User 15.35.1. Hospitals 15.35.2. Clinics 15.35.3. Research Organizations 15.35.4. Others 15.36. Italy Neuropathic Pain Market Forecast, by Type 15.36.1. Peripheral Neuropathy 15.36.2. Entrapment Neuropathy 15.36.3. Phantom Limb Pain 15.36.4. Trigeminal Neuralgia 15.36.5. Post Herpetic Neuralgia 15.36.6. Post Traumatic Neuropathy 15.37. Italy Neuropathic Pain Market Forecast, by Indication 15.37.1. Diabetic Neuropathy 15.37.2. Chemotherapy-Induced Peripheral Neuropathy 15.37.3. Spinal Stenosis 15.38. Italy Neuropathic Pain Market Forecast, by Diagnosis 15.38.1. Imaging 15.38.2. Physical Examination 15.38.3. Blood Tests 15.39. Italy Neuropathic Pain Market Forecast, by Treatment 15.39.1. Medication 15.39.2. Multimodal Therapy 15.40. Italy Neuropathic Pain Market Forecast, By Distribution Channel 15.40.1. Online Pharmacies 15.40.2. Retail Pharmacies 15.40.3. Drug Stores 15.40.4. Others 15.41. Italy Neuropathic Pain Market Forecast, by End-User 15.41.1. Hospitals 15.41.2. Clinics 15.41.3. Research Organizations 15.41.4. Others 15.42. Spain Neuropathic Pain Market Forecast, by Type 15.42.1. Peripheral Neuropathy 15.42.2. Entrapment Neuropathy 15.42.3. Phantom Limb Pain 15.42.4. Trigeminal Neuralgia 15.42.5. Post Herpetic Neuralgia 15.42.6. Post Traumatic Neuropathy 15.43. Spain Neuropathic Pain Market Forecast, by Indication 15.43.1. Diabetic Neuropathy 15.43.2. Chemotherapy-Induced Peripheral Neuropathy 15.43.3. Spinal Stenosis 15.44. Spain Neuropathic Pain Market Forecast, by Diagnosis 15.44.1. Imaging 15.44.2. Physical Examination 15.44.3. Blood Tests 15.45. Spain Neuropathic Pain Market Forecast, by Treatment 15.45.1. Medication 15.45.2. Multimodal Therapy 15.46. Spain Neuropathic Pain Market Forecast, By Distribution Channel 15.46.1. Online Pharmacies 15.46.2. Retail Pharmacies 15.46.3. Drug Stores 15.46.4. Others 15.47. Spain Neuropathic Pain Market Forecast, by End-User 15.47.1. Hospitals 15.47.2. Clinics 15.47.3. Research Organizations 15.47.4. Others 15.48. Rest of Europe Neuropathic Pain Market Forecast, by Type 15.48.1. Peripheral Neuropathy 15.48.2. Entrapment Neuropathy 15.48.3. Phantom Limb Pain 15.48.4. Trigeminal Neuralgia 15.48.5. Post Herpetic Neuralgia 15.48.6. Post Traumatic Neuropathy 15.49. Rest of Europe Neuropathic Pain Market Forecast, by Indication 15.49.1. Diabetic Neuropathy 15.49.2. Chemotherapy-Induced Peripheral Neuropathy 15.49.3. Spinal Stenosis 15.50. Rest of Europe Neuropathic Pain Market Forecast, by Diagnosis 15.50.1. Imaging 15.50.2. Physical Examination 15.50.3. Blood Tests 15.51. Rest Of Europe Neuropathic Pain Market Forecast, by Treatment 15.51.1. Medication 15.51.2. Multimodal Therapy 15.52. Rest Of Europe Neuropathic Pain Market Forecast, By Distribution Channel 15.52.1. Online Pharmacies 15.52.2. Retail Pharmacies 15.52.3. Drug Stores 15.52.4. Others 15.53. Rest Of Europe Neuropathic Pain Market Forecast, by End-User 15.53.1. Hospitals 15.53.2. Clinics 15.53.3. Research Organizations 15.53.4. Others 15.54. Europe Neuropathic Pain Market Attractiveness Analysis 15.54.1. By Type 15.54.2. By Indication 15.54.3. By Diagnosis 15.54.4. By Treatment 15.54.5. By Distribution Channel 15.54.6. By End-User 15.55. PEST Analysis 16. Asia Pacific Neuropathic Pain Market Analysis 16.1. Key Findings 16.2. Asia Pacific Neuropathic Pain Market Overview 16.3. Asia Pacific Neuropathic Pain Market Value Share Analysis, by Type 16.4. Asia Pacific Neuropathic Pain Market Forecast, by Type 16.4.1. Peripheral Neuropathy 16.4.2. Entrapment Neuropathy 16.4.3. Phantom Limb Pain 16.4.4. Trigeminal Neuralgia 16.4.5. Post Herpetic Neuralgia 16.4.6. Post Traumatic Neuropathy 16.5. Asia Pacific Neuropathic Pain Market Value Share Analysis, by Indication 16.6. Asia Pacific Neuropathic Pain Market Forecast, by Indication 16.6.1. Diabetic Neuropathy 16.6.2. Chemotherapy-Induced Peripheral Neuropathy 16.6.3. Spinal Stenosis 16.7. Asia Pacific Neuropathic Pain Market Value Share Analysis, by Diagnosis 16.8. Asia Pacific Neuropathic Pain Market Forecast, by Diagnosis 16.8.1. Imaging 16.8.2. Physical Examination 16.8.3. Blood Tests 16.9. Asia Pacific Neuropathic Pain Market Value Share Analysis, by Treatment 16.10. Asia Pacific Neuropathic Pain Market Forecast, by Treatment 16.10.1. Medication 16.10.2. Multimodal Therapy 16.11. Asia Pacific Neuropathic Pain Market Value Share Analysis, By Distribution Channel 16.12. Asia Pacific Neuropathic Pain Market Forecast, By Distribution Channel 16.12.1. Online Pharmacies 16.12.2. Retail Pharmacies 16.12.3. Drug Stores 16.12.4. Others 16.13. Asia Pacific Neuropathic Pain Market Value Share Analysis, by End-User 16.14. Asia Pacific Neuropathic Pain Market Forecast, by End-User 16.14.1. Hospitals 16.14.2. Clinics 16.14.3. Research Organizations 16.14.4. Others 16.15. Asia Pacific Neuropathic Pain Market Value Share Analysis, by Country 16.16. Asia Pacific Neuropathic Pain Market Forecast, by Country 16.16.1. China 16.16.2. India 16.16.3. Japan 16.16.4. ASEAN 16.16.5. Rest of Asia Pacific 16.17. Asia Pacific Neuropathic Pain Market Analysis, by Country 16.18. China Neuropathic Pain Market Forecast, by Type 16.18.1. Peripheral Neuropathy 16.18.2. Entrapment Neuropathy 16.18.3. Phantom Limb Pain 16.18.4. Trigeminal Neuralgia 16.18.5. Post Herpetic Neuralgia 16.18.6. Post Traumatic Neuropathy 16.19. China Neuropathic Pain Market Forecast, by Indication 16.19.1. Diabetic Neuropathy 16.19.2. Chemotherapy-Induced Peripheral Neuropathy 16.19.3. Spinal Stenosis 16.20. China Neuropathic Pain Market Forecast, by Diagnosis 16.20.1. Imaging 16.20.2. Physical Examination 16.20.3. Blood Tests 16.21. China Neuropathic Pain Market Forecast, by Treatment 16.21.1. Medication 16.21.2. Multimodal Therapy 16.22. China Neuropathic Pain Market Forecast, By Distribution Channel 16.22.1. Online Pharmacies 16.22.2. Retail Pharmacies 16.22.3. Drug Stores 16.22.4. Others 16.23. China Neuropathic Pain Market Forecast, by End-User 16.23.1. Hospitals 16.23.2. Clinics 16.23.3. Research Organizations 16.23.4. Others 16.24. India Neuropathic Pain Market Forecast, by Type 16.24.1. Peripheral Neuropathy 16.24.2. Entrapment Neuropathy 16.24.3. Phantom Limb Pain 16.24.4. Trigeminal Neuralgia 16.24.5. Post Herpetic Neuralgia 16.24.6. Post Traumatic Neuropathy 16.25. India Neuropathic Pain Market Forecast, by Indication 16.25.1. Diabetic Neuropathy 16.25.2. Chemotherapy-Induced Peripheral Neuropathy 16.25.3. Spinal Stenosis 16.26. India Neuropathic Pain Market Forecast, by Diagnosis 16.26.1. Imaging 16.26.2. Physical Examination 16.26.3. Blood Tests 16.27. India Neuropathic Pain Market Forecast, by Treatment 16.27.1. Medication 16.27.2. Multimodal Therapy 16.28. India Neuropathic Pain Market Forecast, By Distribution Channel 16.28.1. Online Pharmacies 16.28.2. Retail Pharmacies 16.28.3. Drug Stores 16.28.4. Others 16.29. India Neuropathic Pain Market Forecast, by End-User 16.29.1. Hospitals 16.29.2. Clinics 16.29.3. Research Organizations 16.29.4. Others 16.30. Japan Neuropathic Pain Market Forecast, by Type 16.30.1. Peripheral Neuropathy 16.30.2. Entrapment Neuropathy 16.30.3. Phantom Limb Pain 16.30.4. Trigeminal Neuralgia 16.30.5. Post Herpetic Neuralgia 16.30.6. Post Traumatic Neuropathy 16.31. Japan Neuropathic Pain Market Forecast, by Indication 16.31.1. Diabetic Neuropathy 16.31.2. Chemotherapy-Induced Peripheral Neuropathy 16.31.3. Spinal Stenosis 16.32. Japan Neuropathic Pain Market Forecast, by Diagnosis 16.32.1. Imaging 16.32.2. Physical Examination 16.32.3. Blood Tests 16.33. Japan Neuropathic Pain Market Forecast, by Treatment 16.33.1. Medication 16.33.2. Multimodal Therapy 16.34. Japan Neuropathic Pain Market Forecast, By Distribution Channel 16.34.1. Online Pharmacies 16.34.2. Retail Pharmacies 16.34.3. Drug Stores 16.34.4. Others 16.35. Japan Neuropathic Pain Market Forecast, by End-User 16.35.1. Hospitals 16.35.2. Clinics 16.35.3. Research Organizations 16.35.4. Others 16.36. ASEAN Neuropathic Pain Market Forecast, by Type 16.36.1. Peripheral Neuropathy 16.36.2. Entrapment Neuropathy 16.36.3. Phantom Limb Pain 16.36.4. Trigeminal Neuralgia 16.36.5. Post Herpetic Neuralgia 16.36.6. Post Traumatic Neuropathy 16.37. ASEAN Neuropathic Pain Market Forecast, by Indication 16.37.1. Diabetic Neuropathy 16.37.2. Chemotherapy-Induced Peripheral Neuropathy 16.37.3. Spinal Stenosis 16.38. ASEAN Neuropathic Pain Market Forecast, by Diagnosis 16.38.1. Imaging 16.38.2. Physical Examination 16.38.3. Blood Tests 16.39. ASEAN Neuropathic Pain Market Forecast, by Treatment 16.39.1. Medication 16.39.2. Multimodal Therapy 16.40. ASEAN Neuropathic Pain Market Forecast, By Distribution Channel 16.40.1. Online Pharmacies 16.40.2. Retail Pharmacies 16.40.3. Drug Stores 16.40.4. Others 16.41. ASEAN Neuropathic Pain Market Forecast, by End-User 16.41.1. Hospitals 16.41.2. Clinics 16.41.3. Research Organizations 16.41.4. Others 16.42. Rest of Asia Pacific Neuropathic Pain Market Forecast, by Type 16.42.1. Peripheral Neuropathy 16.42.2. Entrapment Neuropathy 16.42.3. Phantom Limb Pain 16.42.4. Trigeminal Neuralgia 16.42.5. Post Herpetic Neuralgia 16.42.6. Post Traumatic Neuropathy 16.43. Rest of Asia Pacific Neuropathic Pain Market Forecast, by Indication 16.43.1. Diabetic Neuropathy 16.43.2. Chemotherapy-Induced Peripheral Neuropathy 16.43.3. Spinal Stenosis 16.44. Rest of Asia Pacific Neuropathic Pain Market Forecast, by Diagnosis 16.44.1. Imaging 16.44.2. Physical Examination 16.44.3. Blood Tests 16.45. Rest of Asia Pacific Neuropathic Pain Market Forecast, by Treatment 16.45.1. Medication 16.45.2. Multimodal Therapy 16.46. Rest of Asia Pacific Neuropathic Pain Market Forecast, By Distribution Channel 16.46.1. Online Pharmacies 16.46.2. Retail Pharmacies 16.46.3. Drug Stores 16.46.4. Others 16.47. Rest of Asia Pacific Neuropathic Pain Market Forecast, by End-User 16.47.1. Hospitals 16.47.2. Clinics 16.47.3. Research Organizations 16.47.4. Others 16.48. Asia Pacific Neuropathic Pain Market Attractiveness Analysis 16.48.1. By Type 16.48.2. By Indication 16.48.3. By Diagnosis 16.48.4. By Treatment 16.48.5. By Distribution Channel 16.48.6. By End-User 16.49. PEST Analysis 17. Middle East & Africa Neuropathic Pain Market Analysis 17.1. Key Findings 17.2. Middle East & Africa Neuropathic Pain Market Overview 17.3. Middle East & Africa Neuropathic Pain Market Value Share Analysis, by Type 17.4. Middle East & Africa Neuropathic Pain Market Forecast, by Type 17.4.1. Peripheral Neuropathy 17.4.2. Entrapment Neuropathy 17.4.3. Phantom Limb Pain 17.4.4. Trigeminal Neuralgia 17.4.5. Post Herpetic Neuralgia 17.4.6. Post Traumatic Neuropathy 17.5. Middle East & Africa Neuropathic Pain Market Value Share Analysis, by Indication 17.6. Middle East & Africa Neuropathic Pain Market Forecast, by Indication 17.6.1. Diabetic Neuropathy 17.6.2. Chemotherapy-Induced Peripheral Neuropathy 17.6.3. Spinal Stenosis 17.7. Middle East & Africa Neuropathic Pain Market Value Share Analysis, by Diagnosis 17.8. Middle East & Africa Neuropathic Pain Market Forecast, by Diagnosis 17.8.1. Imaging 17.8.2. Physical Examination 17.8.3. Blood Tests 17.9. Middle East & Africa Neuropathic Pain Market Value Share Analysis, by Treatment 17.10. Middle East & Africa Neuropathic Pain Market Forecast, by Treatment 17.10.1. Medication 17.10.2. Multimodal Therapy 17.11. Middle East & Africa Neuropathic Pain Market Value Share Analysis, By Distribution Channel 17.12. Middle East & Africa Neuropathic Pain Market Forecast, By Distribution Channel 17.12.1. Online Pharmacies 17.12.2. Retail Pharmacies 17.12.3. Drug Stores 17.12.4. Others 17.13. Middle East & Africa Neuropathic Pain Market Value Share Analysis, by End-User 17.14. Middle East & Africa Neuropathic Pain Market Forecast, by End-User 17.14.1. Hospitals 17.14.2. Clinics 17.14.3. Research Organizations 17.14.4. Others 17.15. Middle East & Africa Neuropathic Pain Market Value Share Analysis, by Country 17.16. Middle East & Africa Neuropathic Pain Market Forecast, by Country 17.16.1. GCC 17.16.2. South Africa 17.16.3. Rest of Middle East & Africa 17.17. Middle East & Africa Neuropathic Pain Market Analysis, by Country 17.18. GCC Neuropathic Pain Market Forecast, by Type 17.18.1. Peripheral Neuropathy 17.18.2. Entrapment Neuropathy 17.18.3. Phantom Limb Pain 17.18.4. Trigeminal Neuralgia 17.18.5. Post Herpetic Neuralgia 17.18.6. Post Traumatic Neuropathy 17.19. GCC Neuropathic Pain Market Forecast, by Indication 17.19.1. Diabetic Neuropathy 17.19.2. Chemotherapy-Induced Peripheral Neuropathy 17.19.3. Spinal Stenosis 17.20. GCC Neuropathic Pain Market Forecast, by Diagnosis 17.20.1. Imaging 17.20.2. Physical Examination 17.20.3. Blood Tests 17.21. GCC Neuropathic Pain Market Forecast, by Treatment 17.21.1. Medication 17.21.2. Multimodal Therapy 17.22. GCC Neuropathic Pain Market Forecast, By Distribution Channel 17.22.1. Online Pharmacies 17.22.2. Retail Pharmacies 17.22.3. Drug Stores 17.22.4. Others 17.23. GCC Neuropathic Pain Market Forecast, by End-User 17.23.1. Hospitals 17.23.2. Clinics 17.23.3. Research Organizations 17.23.4. Others 17.24. South Africa Neuropathic Pain Market Forecast, by Type 17.24.1. Peripheral Neuropathy 17.24.2. Entrapment Neuropathy 17.24.3. Phantom Limb Pain 17.24.4. Trigeminal Neuralgia 17.24.5. Post Herpetic Neuralgia 17.24.6. Post Traumatic Neuropathy 17.25. South Africa Neuropathic Pain Market Forecast, by Indication 17.25.1. Diabetic Neuropathy 17.25.2. Chemotherapy-Induced Peripheral Neuropathy 17.25.3. Spinal Stenosis 17.26. South Africa Neuropathic Pain Market Forecast, by Diagnosis 17.26.1. Imaging 17.26.2. Physical Examination 17.26.3. Blood Tests 17.27. South Africa Neuropathic Pain Market Forecast, by Treatment 17.27.1. Medication 17.27.2. Multimodal Therapy 17.28. South Africa Neuropathic Pain Market Forecast, By Distribution Channel 17.28.1. Online Pharmacies 17.28.2. Retail Pharmacies 17.28.3. Drug Stores 17.28.4. Others 17.29. South Africa Neuropathic Pain Market Forecast, by End-User 17.29.1. Hospitals 17.29.2. Clinics 17.29.3. Research Organizations 17.29.4. Others 17.30. Rest of Middle East & Africa Neuropathic Pain Market Forecast, by Type 17.30.1. Peripheral Neuropathy 17.30.2. Entrapment Neuropathy 17.30.3. Phantom Limb Pain 17.30.4. Trigeminal Neuralgia 17.30.5. Post Herpetic Neuralgia 17.30.6. Post Traumatic Neuropathy 17.31. Rest of Middle East & Africa Neuropathic Pain Market Forecast, by Indication 17.31.1. Diabetic Neuropathy 17.31.2. Chemotherapy-Induced Peripheral Neuropathy 17.31.3. Spinal Stenosis 17.32. Rest of Middle East & Africa Neuropathic Pain Market Forecast, by Diagnosis 17.32.1. Imaging 17.32.2. Physical Examination 17.32.3. Blood Tests 17.33. Rest of Middle East & Africa Neuropathic Pain Market Forecast, by Treatment 17.33.1. Medication 17.33.2. Multimodal Therapy 17.34. Rest of Middle East & Africa Neuropathic Pain Market Forecast, By Distribution Channel 17.34.1. Online Pharmacies 17.34.2. Retail Pharmacies 17.34.3. Drug Stores 17.34.4. Others 17.35. Rest of Middle East & Africa Neuropathic Pain Market Forecast, by End-User 17.35.1. Hospitals 17.35.2. Clinics 17.35.3. Research Organizations 17.35.4. Others 17.36. Middle East & Africa Neuropathic Pain Market Attractiveness Analysis 17.36.1. By Type 17.36.2. By Indication 17.36.3. By Diagnosis 17.36.4. By Treatment 17.36.5. By Distribution Channel 17.36.6. By End-User 17.37. PEST Analysis 18. South America Neuropathic Pain Market Analysis 18.1. Key Findings 18.2. South America Neuropathic Pain Market Overview 18.3. South America Neuropathic Pain Market Value Share Analysis, by Type 18.4. South America Neuropathic Pain Market Forecast, by Type 18.4.1. Peripheral Neuropathy 18.4.2. Entrapment Neuropathy 18.4.3. Phantom Limb Pain 18.4.4. Trigeminal Neuralgia 18.4.5. Post Herpetic Neuralgia 18.4.6. Post Traumatic Neuropathy 18.5. South America Neuropathic Pain Market Value Share Analysis, by Indication 18.6. South America Neuropathic Pain Market Forecast, by Indication 18.6.1. Diabetic Neuropathy 18.6.2. Chemotherapy-Induced Peripheral Neuropathy 18.6.3. Spinal Stenosis 18.7. South America Neuropathic Pain Market Value Share Analysis, by Diagnosis 18.8. South America Neuropathic Pain Market Forecast, by Diagnosis 18.8.1. Imaging 18.8.2. Physical Examination 18.8.3. Blood Tests 18.9. South America Neuropathic Pain Market Value Share Analysis, by Treatment 18.10. South America Neuropathic Pain Market Forecast, by Treatment 18.10.1. Medication 18.10.2. Multimodal Therapy 18.11. South America Neuropathic Pain Market Value Share Analysis, By Distribution Channel 18.12. South America Neuropathic Pain Market Forecast, By Distribution Channel 18.12.1. Online Pharmacies 18.12.2. Retail Pharmacies 18.12.3. Drug Stores 18.12.4. Others 18.13. South America Neuropathic Pain Market Value Share Analysis, by End-User 18.14. South America Neuropathic Pain Market Forecast, by End-User 18.14.1. Hospitals 18.14.2. Clinics 18.14.3. Research Organizations 18.14.4. Others 18.15. South America Neuropathic Pain Market Value Share Analysis, by Country 18.16. South America Neuropathic Pain Market Forecast, by Country 18.16.1. Brazil 18.16.2. Mexico 18.16.3. Rest of South America 18.17. South America Neuropathic Pain Market Analysis, by Country 18.18. Brazil Neuropathic Pain Market Forecast, by Type 18.18.1. Peripheral Neuropathy 18.18.2. Entrapment Neuropathy 18.18.3. Phantom Limb Pain 18.18.4. Trigeminal Neuralgia 18.18.5. Post Herpetic Neuralgia 18.18.6. Post Traumatic Neuropathy 18.19. Brazil Neuropathic Pain Market Forecast, by Indication 18.19.1. Diabetic Neuropathy 18.19.2. Chemotherapy-Induced Peripheral Neuropathy 18.19.3. Spinal Stenosis 18.20. Brazil Neuropathic Pain Market Forecast, by Diagnosis 18.20.1. Imaging 18.20.2. Physical Examination 18.20.3. Blood Tests 18.21. Brazil Neuropathic Pain Market Forecast, by Treatment 18.21.1. Medication 18.21.2. Multimodal Therapy 18.22. Brazil Neuropathic Pain Market Forecast, By Distribution Channel 18.22.1. Online Pharmacies 18.22.2. Retail Pharmacies 18.22.3. Drug Stores 18.22.4. Others 18.23. Brazil Neuropathic Pain Market Forecast, by End-User 18.23.1. Hospitals 18.23.2. Clinics 18.23.3. Research Organizations 18.23.4. Others 18.24. Mexico Neuropathic Pain Market Forecast, by Type 18.24.1. Peripheral Neuropathy 18.24.2. Entrapment Neuropathy 18.24.3. Phantom Limb Pain 18.24.4. Trigeminal Neuralgia 18.24.5. Post Herpetic Neuralgia 18.24.6. Post Traumatic Neuropathy 18.25. Mexico Neuropathic Pain Market Forecast, by Indication 18.25.1. Diabetic Neuropathy 18.25.2. Chemotherapy-Induced Peripheral Neuropathy 18.25.3. Spinal Stenosis 18.26. Mexico Neuropathic Pain Market Forecast, by Diagnosis 18.26.1. Imaging 18.26.2. Physical Examination 18.26.3. Blood Tests 18.27. Mexico Neuropathic Pain Market Forecast, by Treatment 18.27.1. Medication 18.27.2. Multimodal Therapy 18.28. Mexico Neuropathic Pain Market Forecast, By Distribution Channel 18.28.1. Online Pharmacies 18.28.2. Retail Pharmacies 18.28.3. Drug Stores 18.28.4. Others 18.29. Mexico Neuropathic Pain Market Forecast, by End-User 18.29.1. Hospitals 18.29.2. Clinics 18.29.3. Research Organizations 18.29.4. Others 18.30. Rest of South America Neuropathic Pain Market Forecast, by Type 18.30.1. Peripheral Neuropathy 18.30.2. Entrapment Neuropathy 18.30.3. Phantom Limb Pain 18.30.4. Trigeminal Neuralgia 18.30.5. Post Herpetic Neuralgia 18.30.6. Post Traumatic Neuropathy 18.31. Rest of South America Neuropathic Pain Market Forecast, by Indication 18.31.1. Diabetic Neuropathy 18.31.2. Chemotherapy-Induced Peripheral Neuropathy 18.31.3. Spinal Stenosis 18.32. Rest of South America Neuropathic Pain Market Forecast, by Diagnosis 18.32.1. Imaging 18.32.2. Physical Examination 18.32.3. Blood Tests 18.33. Rest of South America Neuropathic Pain Market Forecast, by Treatment 18.33.1. Medication 18.33.2. Multimodal Therapy 18.34. Rest of South America Neuropathic Pain Market Forecast, By Distribution Channel 18.34.1. Online Pharmacies 18.34.2. Retail Pharmacies 18.34.3. Drug Stores 18.34.4. Others 18.35. Rest of South America Neuropathic Pain Market Forecast, by End-User 18.35.1. Hospitals 18.35.2. Clinics 18.35.3. Research Organizations 18.35.4. Others 18.36. South America Neuropathic Pain Market Attractiveness Analysis 18.36.1. By Type 18.36.2. By Indication 18.36.3. By Diagnosis 18.36.4. By Treatment 18.36.5. By Distribution Channel 18.36.6. By End-User 18.37. PEST Analysis 19. Company Profiles 19.1. Market Share Analysis, by Company 19.2. Competition Matrix 19.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 19.2.2. New Product Launches and Product Enhancements 19.2.3. Market Consolidation 19.2.3.1. M&A by Regions, Investment and Applications 19.2.3.2. M&A Key Players, Forward Integration and Backward Integration 19.3. Company Profiles: Key Players 19.3.1. Pfizer Inc. 19.3.1.1. Company Overview 19.3.1.2. Financial Overview 19.3.1.3. Product Portfolio 19.3.1.4. Business Strategy 19.3.1.5. Recent Developments 19.3.1.6. Manufacturing Footprint 19.3.2. Johnson and Johnson Services Inc. 19.3.3. Eli Lily and Company 19.3.4. GlaxoSmithKline PLC 19.3.5. Bristol-Myers Squibb 19.3.6. Sanofi SA 19.3.7. Baxter Healthcare Corporation 19.3.8. Biogen Idec Inc. 19.3.9. Astellas Pharma Inc. 19.3.10. AstraZeneca 19.3.11. Abbott Laboratories 19.3.12. Depomed Inc. 19.3.13. Neuroheal Biomedicals, S.L., 19.3.14. Mylan N.V. 19.3.15. ZydusCadila 19.3.16. Amneal Pharmaceuticals LLC 19.3.17. Mayne Pharma Group Limited 19.3.18. Aurobindo Pharma 19.3.19. aurolife, 19.3.20. Mallinckrodt plc 19.3.21. Hikma Pharmaceuticals PLC 19.3.22. ANI Pharmaceuticals, Inc 20. Primary Key Insights

About This Report

Report ID 34992
Category Healthcare
Published Date oct 2019
Updated Date Sep 2020